SLR-108 PET Imaging for Metastatic Solid Tumors
This study is looking at a new way to image metastatic solid tumors (cancers that have spread to other parts of the body) using a special imaging agent called SLR-108. SLR-108 is an antibody-radionuclide conjugate, which means it combines an antibody with a radioactive tracer for PET (positron-emission tomography) scans. Researchers want to find the best dose of SLR-108 and the best time to do the PET scan to get clear images. This study is for adults aged 18 or older who have metastatic solid tumors that have continued to grow despite previous treatments. The study aims to understand the safety, how the drug moves through the body, and the quality of the images. The study plans to enroll 70 participants, but its current status is unclear.
- Study design
- This is an interventional study that plans to enroll 70 participants. It is a Phase 1 study, which means it's an early-stage study to evaluate feasibility.
- What's involved
- You would receive a single intravenous (IV) injection of SLR-108, followed by PET imaging. The primary endpoints are measured through Day 14.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured through Day 14.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07728942
SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors
Recruiting
PHASE1Ages 18+InterventionalDiagnosticSolve Therapeutics
~70 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:SLR-108SLX-1411
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Optimal antibody protein dose
Measured over Through Day 14
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Men or women (as appropriate for cancer type) of age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records.
Based on the most recent tumor assessment, presence of metastatic disease that has progressed during or following previous treatment.
Presence of radiographically measurable disease (defined as the presence of ≥1 non-osseous tumor lesion that measures ≥10 mm in longest dimension \[≥15 mm in shortest dimension for lymph nodes\] and is outside of any prior radiation field).
Prior receipt of commercially available therapies that are indicated for the subject's cancer and have a demonstrated survival benefit for that indication.
Availability of tumor tissue from fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival sample from a previous biopsy.
Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before study drug administration.
Adequate hematological profile.
Adequate coagulation profile.
Adequate hepatic profile.
Adequate renal function.
Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection.
For female subjects of childbearing potential, a negative serum pregnancy test.
For female subjects of childbearing potential, willingness to use a protocol recommended method of contraception from the start of the screening period until ≥6 months after study drug administration.
For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol recommended method of contraception from the start and until ≥6 months after study drug administration and to refrain from sperm donation from the start and until ≥12 months after study drug administration.
Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including any required tumor biopsy/aspirations and all radiographic studies), and study restrictions.
Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the study drug, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion
Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.
Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of study drug administration.
Significant cardiovascular event or comorbidity.
Significant screening ECG abnormalities.
Pregnancy or breastfeeding.
Any medical condition preventing PET/CT scanning, and/or inability to tolerate up to 60 minutes of PET/CT scanning per imaging session, and/or ineligibility for PET/CT scanning due to the weight limits of the scanner.
Major surgery within 4 weeks before study drug administration.
Use of a drug known to prolong the QT interval within 7 days prior to study drug administration.
Anticipated use of a strong inhibitor or inducer of cytochrome CYP3A4 or CYP1A2.
Concurrent participation in another therapeutic or imaging clinical trial.
Any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a subject's ability to provide informed consent, adversely affect the subject's ability to cooperate and participate in the study, or compromise the interpretation of study results.
What this trial measures
- Optimal antibody protein doseThrough Day 14
The appropriate antibody dose (in mg) for optimal imaging
- Optimal administered activityThrough Day 14
The appropriate radioactivity dose (in mCi) for optimal imaging
- Optimal SLR-108 PET timingThrough Day 14
The optimal timing of PET imaging for differentiating tumor tissue from normal background tissue